These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9114194)
21. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Katlama C; De Wit S; O'Doherty E; Van Glabeke M; Clumeck N Clin Infect Dis; 1996 Feb; 22(2):268-75. PubMed ID: 8838183 [TBL] [Abstract][Full Text] [Related]
22. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Caumes E; Bocquet H; Guermonprez G; Rogeaux O; Bricaire F; Katlama C; Gentilini M Clin Infect Dis; 1995 Sep; 21(3):656-8. PubMed ID: 8527561 [TBL] [Abstract][Full Text] [Related]
23. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Dannemann B; McCutchan JA; Israelski D; Antoniskis D; Leport C; Luft B; Nussbaum J; Clumeck N; Morlat P; Chiu J Ann Intern Med; 1992 Jan; 116(1):33-43. PubMed ID: 1727093 [TBL] [Abstract][Full Text] [Related]
24. [Disseminated cerebral haemorrhages in a patient with HIV infection]. Diz S; Barbolla I; Egea M; de Luna G Enferm Infecc Microbiol Clin; 2011 Nov; 29(9):704-5. PubMed ID: 21803458 [No Abstract] [Full Text] [Related]
25. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Kovacs JA Lancet; 1992 Sep; 340(8820):637-8. PubMed ID: 1355212 [TBL] [Abstract][Full Text] [Related]
26. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. Jacobson JM; Hafner R; Remington J; Farthing C; Holden-Wiltse J; Bosler EM; Harris C; Jayaweera DT; Roque C; Luft BJ; AIDS; 2001 Mar; 15(5):583-9. PubMed ID: 11316995 [TBL] [Abstract][Full Text] [Related]
27. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080 [TBL] [Abstract][Full Text] [Related]
28. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624 [TBL] [Abstract][Full Text] [Related]
29. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Saba J; Morlat P; Raffi F; Hazebroucq V; Joly V; Leport C; Vildé JL Eur J Clin Microbiol Infect Dis; 1993 Nov; 12(11):853-6. PubMed ID: 8112357 [TBL] [Abstract][Full Text] [Related]
31. Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. Laing RB; Flegg PJ; Brettle RP; Leen CL; Burns SM Int J STD AIDS; 1996 Jul; 7(4):258-64. PubMed ID: 8876356 [TBL] [Abstract][Full Text] [Related]
32. Criteria for use of atovaquone oral suspension in adult inpatients and outpatients. Goodwin SD; Fish DN Am J Health Syst Pharm; 1995 Nov; 52(21):2460-2. PubMed ID: 8564614 [No Abstract] [Full Text] [Related]
33. Therapeutic approaches for AIDS-related toxoplasmosis. Behbahani R; Moshfeghi M; Baxter JD Ann Pharmacother; 1995; 29(7-8):760-8. PubMed ID: 8520094 [TBL] [Abstract][Full Text] [Related]
37. [Pyrimethamine-sulfadiazine resistant cerebral toxoplasmosis in AIDS]. Huber W; Bautz W; Classen M; Schepp W Dtsch Med Wochenschr; 1995 Jan; 120(3):60-4. PubMed ID: 7828463 [TBL] [Abstract][Full Text] [Related]
38. Chemotherapy of toxoplasmic encephalitis in AIDS patients. Filice G; Carnevale G; Orsolini P; Soldini L; Meroni V; Comolli G; Carenzo L J Chemother; 1989 Jul; 1(4 Suppl):949-50. PubMed ID: 16312718 [No Abstract] [Full Text] [Related]
39. [Value of magnetic resonance in the diagnostic definition of neurotoxoplasmosis and in the assessment of the response to pharmacological treatment]. Sparacia G; Brancatelli G; Sarno C; De Maria M; Lagalla R; Filosto L Radiol Med; 1998; 96(1-2):23-8. PubMed ID: 9819614 [TBL] [Abstract][Full Text] [Related]
40. Management of toxoplasmic encephalitis in HIV-infected adults--a review. Dedicoat M; Livesley N S Afr Med J; 2008 Jan; 98(1):31-2. PubMed ID: 18270637 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]